The experimental drug TEMPOL may be a promising oral antiviral treatment for COVID-19, suggests a study of cell cultures by researchers at the National Institutes of Health.
Speciality biopharmaceutical company Adamis Pharmaceuticals has submitted an Investigational New Drug (IND) to the US Food and Drug Administration (FDA) for the use of Tempol to treat Covid-19.